

CITATION REPORT

List of articles citing

Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients

DOI: 10.1097/ftd.ob013e3181817428

Therapeutic Drug Monitoring, 2008, 30, 504-10.

Source: <https://exaly.com/paper-pdf/45075530/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
76	GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. <i>British Journal of Cancer</i> , 2008 , 99, 1316-21	8.7	24
75	Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?. <i>Pharmacogenomics</i> , 2009 , 10, 1729-32	2.6	13
74	Busulfan in hematopoietic stem cell transplant setting. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 957-69	5.5	76
73	Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. <i>Blood</i> , 2010 , 115, 4597-604	2.2	85
72	Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2010 , 55, 1172-9	3	36
71	Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010 , 107, 570-6	3.1	16
70	Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. <i>Bone Marrow Transplantation</i> , 2010 , 45, 261-7	4.4	57
69	Development of multiplex PCR method for the analysis of glutathione s-transferase polymorphism. <i>Molecular Diagnosis and Therapy</i> , 2011 , 15, 285-92	4.5	4
68	Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1222-30	4.7	42
67	Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. <i>Investigational New Drugs</i> , 2011 , 29, 953-62	4.3	14
66	Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 1429-38	2.9	32
65	An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 1395-410	5.5	15
64	Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. <i>Clinical Cancer Research</i> , 2011 , 17, 6867-77	12.9	44
63	Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2012 , 47, 190-5	4.4	20
62	Predictive performance of a busulfan pharmacokinetic model in children and young adults. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 574-83	3.2	38
61	Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 198-208	3.2	66
60	Pharmacokinetic and pharmacogenetic analysis of oral busulfan in stem cell transplantation: prediction of poor drug metabolism to prevent drug toxicity. <i>Current Drug Safety</i> , 2012 , 7, 211-7	1.4	16

59	Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 944-50	4.7	42
58	Cytostatic drugs in infants: a review on pharmacokinetic data in infants. <i>Cancer Treatment Reviews</i> , 2012 , 38, 3-26	14.4	19
57	Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 331-45	6.2	100
56	Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1608-14	4.7	58
55	Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 991-1000	3.5	8
54	Optimizing drug development of anti-cancer drugs in children using modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 30-47	3.8	23
53	Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. <i>Pharmacogenomics</i> , 2013 , 14, 75-87	2.6	36
52	Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients. <i>Bone Marrow Transplantation</i> , 2013 , 48, 939-46	4.4	34
51	Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 675-83	1.9	14
50	Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Pharmacogenomics</i> , 2013 , 14, 1683-90	2.6	22
49	Predictive performance of a physiologically based pharmacokinetic model of busulfan in children. <i>Pediatric Hematology and Oncology</i> , 2014 , 31, 731-42	1.7	19
48	Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. <i>Haematologica</i> , 2014 , 99, 172-9	6.6	21
47	Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients. <i>Pediatric Blood and Cancer</i> , 2014 , 61, 306-11	3	4
46	Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. <i>Clinical Cancer Research</i> , 2014 , 20, 754-63	12.9	94
45	The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Pharmacogenomics Journal</i> , 2014 , 14, 263-71	3.5	22
44	Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. <i>Drug Discovery Today</i> , 2014 , 19, 1572-86	8.8	47
43	Personalizing busulfan therapy for children undergoing hematopoietic stem cell transplantation. <i>Personalized Medicine</i> , 2014 , 11, 463-466	2.2	
42	Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 493-500	3.2	15

41	New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 680-6	3	12
40	Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 18601-27	6.3	3
39	An analysis of the therapeutic benefits of genotyping in pediatric hematopoietic stem cell transplantation. <i>Future Oncology</i> , 2015 , 11, 833-51	3.6	2
38	Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Pharmacogenomics</i> , 2015 , 16, 1585-94	2.6	20
37	Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1471-8	4.7	32
36	Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 236-45	3.2	51
35	Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoietic Cell Transplant Recipients. <i>Journal of Proteome Research</i> , 2016 , 15, 2802-11	5.6	17
34	Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics. <i>Metabolomics</i> , 2016 , 12, 1	4.7	12
33	Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients. <i>Bone Marrow Transplantation</i> , 2016 , 51, 377-83	4.4	17
32	Gonadotoxic effects of busulfan in two strains of mice. <i>Reproductive Toxicology</i> , 2016 , 59, 31-9	3.4	14
31	Energy landscape of a GSTP1 polymorph linked with cytological function decay in response to chemical stressors. <i>Gene</i> , 2017 , 609, 19-27	3.8	5
30	Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 529-538	3	5
29	Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients. <i>Scientific Reports</i> , 2017 , 7, 1711	4.9	17
28	Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 901-923	5.5	46
27	Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1494-1504	3.8	17
26	Impact of Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Pharmaceutics</i> , 2019 , 11,	6.4	5
25	Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2019 , 110, 355-363	2.3	5
24	Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019 , 124, 691-703	3.1	6

23	Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 293-308	3.5	4
22	Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population. <i>Frontiers in Pharmacology</i> , 2020 , 11, 888	5.6	11
21	Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1819-1827	4.7	5
20	Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation. <i>International Journal of Clinical Pharmacy</i> , 2020 , 42, 703-712	2.3	2
19	A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1499-1509	3.8	7
18	Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 17-51	6.2	9
17	Is Busulfan Clearance Different in Patients With Sickle Cell Disease? Let's Clear Up That Case With Some Controls. <i>Journal of Pediatric Hematology/Oncology</i> , 2021 , 43, e867-e872	1.2	1
16	The analysis of GSTA1 promoter genetic and functional diversity of human populations. <i>Scientific Reports</i> , 2021 , 11, 5038	4.9	5
15	Genetic Predictors for Sinusoidal Obstruction Syndrome-A Systematic Review. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
14	Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 1043-1056	4.5	6
13	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. <i>Oncotarget</i> , 2017 , 8, 90852-90867	3.3	27
12	Characterization of Drug-Drug Interactions on the Pharmacokinetic Disposition of Busulfan in Pediatric Patients during Hematopoietic Stem Cell Transplantation Conditioning. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	0
11	Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance. <i>European Journal of Cancer</i> , 2021 ,	7.5	2
10	Influence of , , and genetic polymorphisms on disorders in transplant patients: a systematic review. <i>Drug Metabolism and Personalized Therapy</i> , 2021 ,	2	
9	Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation.. <i>Transplantation and Cellular Therapy</i> , 2022 ,		0
8	Busulfan dose recommendation in inherited metabolic disorders: Population pharmacokinetic analysis: Busulfan PK model in inherited metabolic disease. <i>Transplantation and Cellular Therapy</i> , 2021 , 28, 104.e1-104.e1		1
7	Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia.. <i>Frontiers in Pediatrics</i> , 2021 , 9, 775485	3.4	2
6	DataSheet_1.docx. 2020 ,		

5	Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation. <i>Pharmaceutics</i> , 2022 , 14, 1145	6.4	
4	The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study. <i>Frontiers in Pharmacology</i> , 13,	5.6	
3	The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review. <i>Pharmacogenomics and Personalized Medicine</i> , Volume 15, 675-696	2.1	○
2	External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients. <i>Frontiers in Pharmacology</i> , 13,	5.6	
1	Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions. 2023 , 19, 75-90		○